Source comparison
Best KPV Dosage IBD Support 2026: Protocol Comparison
This table compares published KPV dosing protocols for IBD research models, with practical notes on reconstitution and administration logistics most protocols omit. | Protocol Type | Dose per Administration | Frequency | Route | Peptide Stability Window | Prac
This comparison does not assign a generated winner or score.
- This table compares published KPV dosing protocols for IBD research models, with practical notes on reconstitution and administration logistics most protocols omit.
- | Protocol Type | Dose per Administration | Frequency | Route | Peptide Stability Window | Practical Limitation | Bottom Line ||—|—|—|—|—|—|| Standard Low-Dose | 500mcg (25g mouse) | Once daily | Subcutaneous | 7–10 days post-reconstitution | Short plasma half-life limits coverage to ~2 hours/day | Suitable for mild inflammation models or dose-finding studies; insufficient for severe colitis || Split-Dose Standard | 250mcg (25g mouse) | Twice daily (12hr intervals) | Subcutaneous | 7–10 days post-reconstitution | Requires twice-daily handling and injection stress | Best balance of plasma coverage and peptide economy for moderate IBD models || High-Dose Escalation | 2mg (25g mouse) | Once daily | Subcutaneous | 7–10 days post-reconstitution | Dose exceeds plateau region of dose-response curve; minimal additional benefit over 1mg | Use only in refractory inflammation models where standard doses show suboptimal response || Oral Gavage Alternative | 5mg (25g mouse) | Once daily | Oral gava